Babaei A, Eslamai M H
Department of Pharmacology, Yazd University of Medical Sciences, Yazd, Iran.
Int J Clin Pharmacol Ther. 2007 Feb;45(2):121-5. doi: 10.5414/cpp45121.
The antiepileptic drugs phenobarbital, phenytoin and carbamazepine are widely used for the treatment of partial and tonic-clonic seizures. Large inter-individual differences in pharmacokinetics of these drugs, and the intermittent nature of epileptic attacks, increase the need for therapeutic drug level monitoring of these drugs.
In this study, data from the therapeutic drug monitoring of phenobarbital, carbamazepine and phenytoin in 328 epileptic patients were evaluated. Serum levels of drugs were determined in a University Department of Pharmacology by high-performance liquid chromatography.
In this study, approximately 56% of patients were treated with 1; 30% with 2; and 14% with 3 antiepileptic drugs. In patients receiving 1 antiepileptic drug, the percentages treated with phenobarbital, carbamazepine and phenytoin were 41, 38 and 21%, respectively. In patients who received carbamazepine, serum levels in 40% of the patients were in the range of 4-8 microg/ml and more than in the range 4-12 microg/ml in 74% of the patients. In phenobarbital-treated patients, serum levels in 73% of the patients were in therapeutic range of 10-40 microg/ml, and about 44% of phenytoin-treated patients had serum levels in therapeutic range of 10-20 microg/ml. Approximately 50% of carbamazepine- and phenytoin-treated patients and approximately 70% of phenobarbital-treated patients were completely controlled. The frequency of concentrations within the therapeutic ranges decreased in patients using more than 1 antiepileptic drug. In patients who received both phenobarbital and sodium valproate, serum levels of phenobarbital were significantly (p < 0.05) greater than in patients who were taking this drug in combination with carbamazepine or phenytoin.
Our results indicate that serum levels of antiepileptic drugs, and the percentage of patients with complete seizure control are comparable with results obtained in other populations in previous studies.
抗癫痫药物苯巴比妥、苯妥英和卡马西平广泛用于治疗部分性发作和强直阵挛性发作。这些药物的药代动力学存在较大个体差异,且癫痫发作具有间歇性,这增加了对这些药物进行治疗药物浓度监测的必要性。
本研究评估了328例癫痫患者苯巴比妥、卡马西平和苯妥英治疗药物监测的数据。药物血清浓度在大学药理学系通过高效液相色谱法测定。
本研究中,约56%的患者接受1种抗癫痫药物治疗;30%接受2种;14%接受3种。在接受1种抗癫痫药物治疗的患者中,接受苯巴比妥、卡马西平和苯妥英治疗的患者比例分别为41%、38%和21%。在接受卡马西平治疗的患者中,40%的患者血清浓度在4 - 8μg/ml范围内,74%的患者血清浓度在4 - 12μg/ml范围内。在接受苯巴比妥治疗的患者中,73%的患者血清浓度在10 - 40μg/ml治疗范围内,约44%接受苯妥英治疗的患者血清浓度在10 - 20μg/ml治疗范围内。约50%接受卡马西平和苯妥英治疗的患者以及约70%接受苯巴比妥治疗的患者癫痫发作得到完全控制。使用超过1种抗癫痫药物的患者中,治疗范围内浓度的频率降低。在同时接受苯巴比妥和丙戊酸钠治疗的患者中,苯巴比妥的血清浓度显著高于(p < 0.05)与卡马西平或苯妥英联合使用该药物的患者。
我们的结果表明,抗癫痫药物的血清浓度以及癫痫发作完全得到控制的患者百分比与先前研究中其他人群的结果相当。